You have 9 free searches left this month | for more free features.

Higher-Risk (HR) Myelodysplastic Syndromes (MDS)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

Recruiting
  • MDS/MPN
  • Azacitidine (AZA) with Ruxolitinib
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 17, 2023

Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

Not yet recruiting
  • Untreated Myelodysplastic Syndrome
  • Onureg + Venetoclax
  • Angers, France
  • +9 more
Mar 13, 2023

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +3 more
Nov 21, 2023

MDS Trial in Hefei (Unrelated Umbilical Cord Blood, Venetoclax, Decetabine)

Recruiting
  • Myelodysplastic Syndromes
  • Unrelated Umbilical Cord Blood
  • +3 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of University of Science and Techn
Oct 27, 2023

MDS Trial in Houston (Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2023

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)

Not yet recruiting
  • Higher Risk Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia
  • (no location specified)
Jul 29, 2022

MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 2, 2022

Acute Myeloid Leukemia, MDS Trial in Rochester, Houston (CTX-712)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Rochester, Minnesota
  • +1 more
Feb 15, 2023

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul

Active, not recruiting
  • Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

MDS Trial in New Haven (CPX-351)

Withdrawn
  • MDS
  • New Haven, Connecticut
    Yale University; Smilow Cancer Center
Jan 6, 2022

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

Active, not recruiting
  • Myelodysplastic Syndromes
  • cyclophosphamide, fludarabine, and antithymocyte globulin
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

MDS Trial (Roxadustat in combination with retinoic acid)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Roxadustat in combination with retinoic acid
  • (no location specified)
Aug 26, 2023

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

MDS Trial (Imetelstat)

Available
  • Myelodysplastic Syndromes
  • (no location specified)
Jun 30, 2023

AML, Adult, MDS, Relapse/Recurrence Trial in United States (BST-236)

Recruiting
  • AML, Adult
  • +3 more
  • Shreveport, Louisiana
  • +3 more
Jul 19, 2022

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022